摘要
目的制定甲状腺功能亢进症(简称甲亢)患者疾病管理知信行(KAP)模型量表,并初步调研患者的疾病管理现状,为科普干预甲亢患者用药,优化其治疗方案的必要性提供依据。方法采用德尔菲法设计KAP问卷,对北京市3家三级甲等医院的148例甲亢患者进行问卷调查。问卷包含知识、信念和行为3个部分,每个部分各有8个条目。问卷各个部分最终得分均按百分制计算,百分制得分=实际得分/总分×100,其中,<60分为差,60~79分为中,≥80分为良好。结果患者知识维度平均得分为(35.81±18.13)分、信念维度平均得分为(84.10±12.63)分、行为维度平均得分为(50.40±12.78)分,提示甲亢患者疾病认知能力较差,用药行为管理能力欠佳,但治疗信念态度积极。结论甲亢患者对疾病及用药的认知水平较低,渴望得到用药指导。建议通过多种形式对患者进行科普干预,并优化其药物治疗方案。
Objective This study was designed to develop a knowledge,attitude and practice(KAP)scaling model suit⁃able for hyperthyroidism patients,and a preliminary investigation on the disease management of hyperthyroidism patients was conducted to provide the basis for the necessity of health education on drug interventions of hyperthyroidism patients and opti⁃mization of their therapeutic regimens.Methods KAP status of antithyroid drug interventions among 148 hyperthyroidism pa⁃tients from 3 top hospitals in Beijing was investigated via questionnaire developed by Delphi method.The questionnaire con⁃sisted of knowledge,attitude and practice sections with 8 questions in each section.The final scores of each section were scaled by the following equation:hundred-mark score=observed score/total score×100,where<60 is poor,60-79 is moder⁃ate,and≥80 is good.Results The average knowledge score of hyperthyroidism patients was 35.81±18.13,the average atti⁃tude score was 84.10±12.63,and the average practice score was 50.40±12.78.These results suggested that the patients with hyperthyroidism have little knowledge on the disease and poor behavior management,but they have a positive attitude.Conclu⁃sion Hyperthyroidism patients lack knowledge on antithyroid drugs medication and are eager to receive guidance on medica⁃tion education.We recommend that various forms of health education on antithyroid drug medication should be provided to optimize their regimens.
作者
赵喆
王新峰
王硕
巩红
唐筱婉
刘容吉
梅丹
唐彦
ZHAO Zhe;WANG Xin-feng;WANG Shuo;GONG Hong;TANG Xiao-wan;LIU Rong-ji;MEI Dan;TANG Yan(Department of Pharmary,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China;Institute of Materia Medica,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100050,China;Department of Thoracic Surgery,National Cancer Center,National Clinical Research Center for Cancer,Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)
出处
《临床药物治疗杂志》
2021年第8期80-84,共5页
Clinical Medication Journal
